COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    NCT04050137
Previous Study | Return to List | Next Study

Therapeutic Exercise to Treat Neuropathic Pain (Aps)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04050137
Recruitment Status : Active, not recruiting
First Posted : August 8, 2019
Last Update Posted : February 5, 2020
fundación española para el estudio y tratamiento de la Enfermedad de Gaucher y otras lisosomales
Fundación San Valero
Fundación Ibercaja
Information provided by (Responsible Party):
Maria Pilar López Royo, Universidad de Zaragoza

Brief Summary:
A quasi-experimental, prospective clinical trial with pre and post intervention measurements, whose porpuose is assess the efficacy of a therapeutic exercise protocol to treat neuropathic pain in Fabry Disease.

Condition or disease Intervention/treatment Phase
Gaucher Disease Fabry Disease Other: Therapeutic Exercise Not Applicable

Detailed Description:
There take part in this study women or men aged between 18 and 65 years, with a diagnosys by a physician specializing in Fabry disease with FabryScan. Patients must present a stable evolution, with a scoring system of disease severity (DS3) that must be less than 8 points per year in the last 2-3 years and they have to presence of neuropathic pain with a score greater than or equal to 4 in the questionnaire "Douleur neuropathique (DN4)".

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Therapeutic Exercise to Treat Neuropathic Pain in Patients With Chronic Lisosomal Injuries: Learning and Service Project
Actual Study Start Date : May 2, 2019
Estimated Primary Completion Date : December 30, 2020
Estimated Study Completion Date : December 1, 2021

Arm Intervention/treatment
Experimental: Exercise group
Exercise programme 3 times/week.
Other: Therapeutic Exercise

Patients who meet the inclusion criteria and who want to carry out the workshops, fill out an informed consent explaining the procedure to be followed and accepting the cessation of data to carry out the study.

Patients will be divided into 2 working groups (approximately 10 patients in total, in a Gaucher disease group and in another Fabry disease). The workshops will be held at the foundation twice a month in sessions of 45 minutes of work for 3 months (May, June, July 2019). In these sessions the physiotherapists will show the new exercises to the patients. The exercises that are taught in that session should be done at home 3 times a week. In addition, a document will be delivered with the exercises to be carried out and the frequency and intensity of execution. The workshops will be guided at all times by a physiotherapist specialized in therapeutic exercise and EDL.

Primary Outcome Measures :
  1. Neurophatic pain [ Time Frame: 8 weeks ]
    DN4. This tool allows to estimate the probability of neuropathic pain of the patient in a valid and reliable way. It consists of 4 questions with 10 items to fill out. The researcher directly asks the patient and it is the investigator who completes the questionnaire. To each item, you must provide a "yes" or "no" answer; the "yes" is worth 1 point and the "no" is worth 0 point. At the end of the questionnaire, the investigator counts the patient's score on 10. If the patient's score is equal to or greater than 4 out of 10, the test is positive.

Secondary Outcome Measures :
  1. Functionality [ Time Frame: 8 weeks ]
    Arm Functionality DASH. The DASH questionnaire is a tool for assessing and measuring the functionality of the upper limb that the patient perceives during daily activities. This questionnaire is used in several studies with patients with disabilities in the hand, elbow and shoulder. It is valid, reliable and capable of detecting changes.

  2. Legs' strenght [ Time Frame: 8 weeks ]
    Test of rising and sitting of the chair during 30 seconds as many times as possible.

  3. Strenght of the extensor muscless of the trunk [ Time Frame: 8 weeks ]
    BST. Biering-Sorensen test.The test is to keep the trunk in prone position as long as possible to assess the resistance of the trunk extensor musculature.

  4. Strenght of the inclination muscless of the trunk [ Time Frame: 8 weeks ]
    TSB. Test Side-Bridge assesses the resistance of the inclination muscles or lateral flexors of the trunk. In it the participants are placed in lateral recumbency on their dominant side in a mat. In this position, the participants support themselves with the elbow and the forearm of their dominant side and raise the pelvis until the trunk is aligned with the lower extremities. The test consists of maintaining the referred position as long as possible.

  5. Strenght of the flexor muscless of the trunk [ Time Frame: 8 weeks ]
    ITo. To assess the resistance of the flexor muscles of the trunk, the participants are placed supine with the hips and knees bent at 90º. The participants flex the upper part of the trunk until they touch the thighs with the elbows, keeping the cervical spine in a neutral position.

  6. Visual Analogue Scale [ Time Frame: 8 weeks ]

    VAS. The analog visual pain scale is a tool that is used to assess the pain perceived by the patient in a valid and reliable way.

    It is an instrument for measuring the intensity of pain that represents a horizontal line of 10 cm with a score of 0 to 10, where 0 represents non-pain and 10 unbearable pain.

    The patient should place a vertical line on the horizontal line of the scale where he places his pain intensity.

  7. Hospital, anxiety and depression questionnaire [ Time Frame: 8 weeks ]
    HADS. This questionnaire allows to evaluate the psychosocial factors of the patient, through 14 questions with two subscales of 7 questions (one subscale on anxiety and the other on depression); The patient must answer one of the 4 items of each question without much reflection to have a real answer of how he was during the past week. The intensity or frequency of symptoms is evaluated with a Likert scale ranging from 0 to 3. In each subscale (anxiety and depression) the points are added and interpreted as such: 0-7 points: normal; 8-10 points: doubtful and higher than 11: clinical problem. This tool is validly and reliably used in clinical practice.

  8. SF-36 [ Time Frame: 8 weeks ]
    This questionnaire assesses the quality of life perceived by the patient. It is widely used in clinical practice and is approved as valid and reliable. There are 36 questions with 2,3,5 or 6 items in each question and with an assessment between 0 and 100. The questions assess physical function, function limitations due to physical health problems, body aches, general health, vitality, social functioning and emotional and mental health problems

  9. Semmes Weinstein monofilament test [ Time Frame: 8 weeks ]

    The Semmes Weinstein monofilament test is a tool that evaluates tactile and pressure sensitivity in a valid and reliable way. A nylon filament attached to a handle is used which, when folded, applies a constant pressure of 10g. The investigator applies the monofilament perpendicular to the skin with increased pressure until the monofilament bends and without supporting it for more than 1 or 2 seconds.

    The test will be performed on the sole of the foot in 4 points: the first toe, the base of the first, third and fifth metatarsals.

    When the patient notices something, he puts a 1 and a 0 if he does not notice something. The sensitivity index is obtained with the sum of the values and is considered a sensitive patient only when it has a score of 8/8.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Female or male patients between 18 years and 65 years.
  • Patients diagnosed by a doctor specializing in Fabry disease with FabryScan.
  • Fabry's disease must have a stable evolution, with a disease severity scoring system (DS3) that must be less than 8 points per year in the last 2-3 years.
  • Presence of neuropathic pain with a score greater than or equal to 4 in the "Douleur neuropathique (DN4)" questionnaire.

Exclusion criteria:

  • Patients with an acute cardiovascular disease or with a heart or kidney transplant.
  • Subjects with acute orthopedic problems that limit their participation in the study.
  • Subjects with cognitive impairments that prevent them from filling in the questionnaires or understanding the exercises to be performed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04050137

Layout table for location information
Zaragoza, Spain
Sponsors and Collaborators
Universidad de Zaragoza
fundación española para el estudio y tratamiento de la Enfermedad de Gaucher y otras lisosomales
Fundación San Valero
Fundación Ibercaja
Layout table for investigator information
Principal Investigator: Royo Universidad San Jorge
Layout table for additonal information
Responsible Party: Maria Pilar López Royo, Principal Investigator, Universidad de Zaragoza Identifier: NCT04050137    
Other Study ID Numbers: PI19/205
First Posted: August 8, 2019    Key Record Dates
Last Update Posted: February 5, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Maria Pilar López Royo, Universidad de Zaragoza:
Gaucher Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Fabry Disease
Gaucher Disease
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Cerebral Small Vessel Diseases
Cerebrovascular Disorders
Vascular Diseases
Cardiovascular Diseases
Genetic Diseases, X-Linked
Genetic Diseases, Inborn
Metabolism, Inborn Errors
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases
Lipid Metabolism Disorders